Showing 731-740 of 2293 results for "".
- Climate Change May Worsen Neurologic Disease Symptomshttps://practicalneurology.com/news/climate-change-may-worsen-neurologic-disease-symptoms/2470067/According to a review of published studies on climate change, people with neurologic diseases such as migraine, dementia, Multiple Sclerosis (MS), and Parkinson disease (PD) may experience worsening symptoms and stroke may be more prevalent due to climate change. The review
- Virtual Reality Technology is Feasible for Treating Upper Limb Dysfunction in Multiple Sclerosishttps://practicalneurology.com/news/virtual-reality-technology-is-feasible-for-treating-upper-limb-dysfunction-in-multiple-sclerosis/2470056/Results from a new study published in JMIR Serious Games shows that virtual reality technology is safe and improves functionality for upper limb dysfunction in individuals with Multiple Sclerosis (MS). The software is safe, reliable, and engaging. "The study proves that virtual rea
- Long-Term Efficacy and Safety of Evobrutinib for Multiple Sclerosis Results Over 144-Week Clinical Studieshttps://practicalneurology.com/news/long-term-efficacy-and-safety-of-evobrutinib-for-multiple-sclerosis-results-over-144-week-clinical-studies/2469930/In the open-label extension of a phase 2 clinical trial (NCT02975349), participants with multiple sclerosis (MS) treated with the investigational Bruton tyrosine kinase inhibitor evobrutinib (EMD Serono, Rockland, MA) continued to have a low annualized relapse rate (ARR). For individuals treated
- Translingual Neuromodulator to Assist Ambulation in Multiple Sclerosis Now Available in UShttps://practicalneurology.com/news/translingual-neuromodulator-to-assist-ambulation-in-multiple-sclerosis-now-available-in-us/2469898/Helius Medical Technologies (Newtown, PA) has announced that their translingual neuromodulation (portable neuromodulation stimulator [PONS]) device, shown to assist walking in people with multiple sclerosis (MS), is now available in the US. The PONS device is a portable, nonimplant neuromod
- Evobrutinib Reduces Relapsing Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/evobrutinib-reduces-relapsing-multiple-sclerosis-disease-activity/2469723/Post-hoc analysis of data from a phase 2 study (NCT02975349) of evobrutinib (M2951; EMD Serono, Rockland, MA) reduced the volume of slowly expanding MRI lesions in participants with relapsing multiple sclerosis (MS). Slowly expanding l
- Tolebrutinib Treatment Lowered Disease Activity of Relapsing Multiple Sclerosishttps://practicalneurology.com/news/tolebrutinib-treatment-lowered-disease-activity-of-relapsing-multiple-sclerosis/2469721/In a phase 2b study, participants with relapsing multiple sclerosis (RMS) treated with tolebrutinib (SAR442168; Sanofi, Bridgewater, NJ) had reduced MS disease activity measured by MRI. Participants received 5, 15, 30, or 60 mg/day tolebrutinib for 14 weeks and then 60 mg/day for the following 34
- Game-Based Digital Therapy for Individuals With Multiple Sclerosis Reduces Anxietyhttps://practicalneurology.com/news/game-based-digital-therapy-for-individuals-with-multiple-sclerosis-reduces-anxiety/2469670/Use of a game-based digital therapy (Personal Zen; Wise Therapeutics, New York, NY) reduced symptoms of anxiety in individuals with multiple sclerosis (MS). The digital therapy requires a prescription and uses adaptive, personalized gameplay to address mental health needs, and can serve as an at-
- Natalizumab Every 6 Weeks Is Effective for Treatment of Multiple Sclerosis and Reduces Riskhttps://practicalneurology.com/news/natalizumab-every-6-weeks-is-effective-for-treatment-of-multiple-sclerosis-and-reduces-risk/2469657/Treatment of multiple sclerosis (MS) with 300 mg natalizumab (Tysabri; Biogen, Cambridge, MA) every 6 weeks vs every 4 weeks was evaluated in the phase 3b NOVA study (NCT03689972). Both dosing intervals were found equally effective in
- Immune Repopulation Study Suggests Cladribine Has No Negative Effect on Ability to Fight Injection or Benefit From Vaccinationhttps://practicalneurology.com/news/immune-repopulation-study-suggests-cladribine-has-no-negative-effect-on-ability-to-fight-injection-or-benefit-from-vaccination/2469580/New research suggests that cladribine (Mavenclad; Merck KGaA, Darmstadt, Germany) treatment for relapsing multiple sclerosis (RMS) does not diminish individuals' ability to fight infection or form antibodies after immunization. The MAGNIFY-MS sub-study (
- Vidofludimus Calcium a Selective T- and B-Cell Reduced Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/vidofludimus-calcium-a-selective-t-and-b-cell-reduced-multiple-sclerosis-disease-activity/2469566/In the phase 2 EMPhASIS trial (NCT03846219) vidofludimus calcium (VFC)(IMU-838; Immunic, New York, NY) reduced new combined unique active (CUA) MRI lesions in individuals with multiple sclerosis (MS). CUA is a measure that counts uniqu